This company wants to make treating peanut allergies as easy as brushing your teeth
That's the plan for Intrommune, a new New York-based biotechnology company that recently acquired the rights to license the toothpaste technology they intend to apply to food allergies.
Allergies are your immune system's response to a substance that may not be harmful to others. They're also the sixth leading cause of chronic disease in the US. In the case of peanut allergies, some people can be so severely allergic that they have a reaction if they even inhale some peanut particles.And because so many with severe allergies are kids, the stigma of being sick can be a lot to handle. But what if instead of having to take a pill, all they had to do was brush their teeth as they would any other day?
"They don't have to feel like they're sick," Danya Glabau, Intrommune's director of medical affairs, told Business Insider. "They're not doing anything different from their friends."
Retraining the immune system
In some people, one of the best ways calm down these reactions is to de-sensitize the person to the allergen through immunotherapy. That involves using small doses to introduce the person - and his or her immune system - to whatever they're allergic to in the hopes that they'll be able to re-train their immune system to react less strongly to the allergen over time.
Allergy immunotherapy is in no way a new concept. It's been practiced in one way or another for more than a century. In the case of the toothpaste, its goal is to be delivered through the oral mucosa, or the mucous membrane that lines our mouths.
The idea with allergy immunotherapy is that in time as the dose is slowly increased, desensitization builds. But because the treatments typically need to be given to people for as long as three to five years, it can be hard to get people to stick with it and incorporate it into their daily routines. And that's where the toothpaste comes in.
In a new study published this month in the journal Allergy & Rhinology, Reisacher and his team showed that the toothpaste method was safe and effective in treating those respiratory allergies in comparison to traditional sublingual immunotherapy, where drops are given under the tongue. The small study, which looked at 24 people who were either given the toothpaste or the drops, is meant to set up future, larger-scale trials.
For now, the Intrommune is just in the beginning stages of developing the toothpaste for food allergies. First, they'll need to develop a peanut with a consistent makeup (that way, they know just how much of the peanut protein is going into the toothpaste). Then, they plan to get started with clinical trials in their journey toward FDA approval, starting with peanuts, but expanding out to the other top food allergies, such as soy, wheat, milk, and eggs.
Then, of course, they'll need to figure out a kid-friendly flavor - right now the toothpaste comes in a mint flavor only.